Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes.

Autor: Riviere, Marie‐Emmanuelle, Langbaum, Jessica B., Turner, R. Scott, Rinne, Juha O., Sui, Yihan, Cazorla, Pilar, Ricart, Javier, Meneses, Kathleen, Caputo, Angelika, Tariot, Pierre N., Reiman, Eric M., Graf, Ana

Publikováno v: Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Mar2024, Vol. 20 Issue 3, p1839-1850, 12p

[Retracted] Cognitive improvements and reduction in amyloid plaque deposition by saikosaponin D treatment in a murine model of Alzheimer's disease.

Autor: Zhou L, Huang JY, Zhang D, Zhao YL

Publikováno v: Experimental and therapeutic medicine [Exp Ther Med] 2024 Aug 05; Vol. 28 (4), pp. 387. Date of Electronic Publication: 2024 Aug 05 (Print Publication: 2024).

Early loss of locus coeruleus innervation promotes cognitive and neuropathological changes before amyloid plaque deposition in a transgenic rat model of Alzheimer's disease.

Autor: Flores‐Aguilar, Lisi¹ (AUTHOR), Hall, Hélène² (AUTHOR), Orciani, Chiara³ (AUTHOR), Foret, Morgan K.² (AUTHOR), Kovecses, Olivia² (AUTHOR), Ducatenzeiler, Adriana² (AUTHOR), Cuello, A. Claudio^1,2,3,4 (AUTHOR) claudio.cuello@mcgill.ca

Publikováno v: Neuropathology & Applied Neurobiology. Oct2022, Vol. 48 Issue 6, p1-16. 16p.

Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes.

Autor: Riviere ME; Clinical Development, Neuroscience, Novartis Pharma AG, Basel, Switzerland., Langbaum JB; Banner Alzheimer's Institute, Phoenix, Arizona, USA., Turner RS; Department of Neurology, Georgetown University Medical Center, Washington, District of Columbia, USA., Rinne JO; Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.; Department of Neurology, CRST - Clinical Research Services Turku, Turku, Finland., Sui Y; Clinical Development, Neuroscience, Novartis Pharmaceuticals, East Hanover, New Jersey, USA., Cazorla P; Clinical Development, Neuroscience, Novartis Pharmaceuticals, East Hanover, New Jersey, USA., Ricart J; Clinical Development, Neuroscience, Novartis Farmaceutica SA, Barcelona, Spain., Meneses K; Clinical Development, Neuroscience, Novartis Pharmaceuticals, East Hanover, New Jersey, USA., Caputo A; Clinical Development, Neuroscience, Novartis Pharma AG, Basel, Switzerland., Tariot PN; Banner Alzheimer's Institute, Phoenix, Arizona, USA., Reiman EM; Banner Alzheimer's Institute, Phoenix, Arizona, USA., Graf A; Clinical Development, Neuroscience, Novartis Pharma AG, Basel, Switzerland.

Publikováno v: Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Mar; Vol. 20 (3), pp. 1839-1850. Date of Electronic Publication: 2023 Dec 25.

Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition

Autor: Cabrera, Erwin, Mathews, Paul, Mezhericher, Emiliya, Beach, Thomas G., Deng, Jingjing, Neubert, Thomas A., Rostagno, Agueda, Ghiso, Jorge

Publikováno v: In BBA - Molecular Basis of Disease January 2018 1864(1):208-225